logo
Plus   Neg
Share
Email
Comment

Agios Pharmaceuticals Files For IPO Of Up To $86 Mln

Biopharmaceutical company Agios Pharmaceuticals Inc has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission to raise up to $86 million in an initial public offering of common stock. The company did not specify the number of shares to be sold and the price range for the proposed offering.

The Cambridge, Massachusetts-based company said in a preliminary prospectus that it intends to list its common stock on the Nasdaq under the symbol "AGIO".

The company, which was founded in 2007, specified that JP Morgan and Goldman Sachs & Co are lead underwriters in the IPO.

In April 2010, Agios entered into a collaboration agreement with Celgene corp (CELG.O) on a program focused on cancer metabolism.

Agios reported a net loss of $7.2 million on revenue of $6.3 million for the quarter ended March 31, according to the filing.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Dish Network Corp. on Wednesday reported a surge in profit for the fourth quarter from last year, reflecting an income tax benefit that helped offset the impact of lower revenues. The latest quarter's results were positively impacted by an income tax benefit of about $1.2 billion due to an adjustment to deferred tax assets and liabilities related to tax reform legislation. Shares of Glencore plc were gaining around 4 percent in the morning trading in London after the producer and marketer of commodities reported Wednesday a significant growth in fiscal 2017 profit on strong higher commodity prices. Chief Executive Officer Ivan Glasenberg said, "Our performance in 2017 was our strongest on record, driven by our leading Marketing and Industrial asset businesses." Shares of Orange SA were gaining around 2 percent in the early morning trading in Paris after the French telecom major reported Wednesday a significant growth in fiscal 2017 profit from continuing operations with revenue growth in most regions, mainly France and Spain. In France, revenue grew for the first time since 2009. Attributable net income, meanwhile, declined on the absence of prior
comments powered by Disqus
Follow RTT